Interpace Biosciences Inc Net debt/EBITDA
Quel est le Net debt/EBITDA de Interpace Biosciences Inc?
Le Net debt/EBITDA de Interpace Biosciences Inc est -1.57
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur NASDAQ par rapport à Interpace Biosciences Inc
Que fait Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Entreprises avec net debt/ebitda similaire à Interpace Biosciences Inc
- Athabasca Oil a Net debt/EBITDA de -1.59
- Limbach Inc a Net debt/EBITDA de -1.58
- Batero Gold a Net debt/EBITDA de -1.58
- MGC Pharmaceuticals a Net debt/EBITDA de -1.58
- QS a Net debt/EBITDA de -1.58
- Simply a Net debt/EBITDA de -1.58
- Interpace Biosciences Inc a Net debt/EBITDA de -1.57
- Super Micro Computer Inc a Net debt/EBITDA de -1.57
- NexgenRx a Net debt/EBITDA de -1.57
- PostNL N.V a Net debt/EBITDA de -1.56
- Magontec a Net debt/EBITDA de -1.56
- Metalla Royalty & Streaming a Net debt/EBITDA de -1.55
- Invo Bioscience Inc a Net debt/EBITDA de -1.55